Safety of autologous Schwann cell transplantation demonstrated following SCI

Home/News/News/Safety of autologous Schwann cell transplantation demonstrated following SCI

Safety of autologous Schwann cell transplantation demonstrated following SCI

A Phase I clinical trial that targeted individuals with new onset paraplegia to evaluate the safety of transplanting their own potentially neuroprotective Schwann cells into a trauma-induced spinal cord lesion showed no evidence of adverse effects after 1 year. This novel cell therapy approach for treating subacute thoracic spinal cord injury is described in an article in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Neurotrauma website until April 22, 2017.


Original source of this content: https://www.eurekalert.org/pub_releases/2017-03/mali-soa032217.php